Imatinib mesylate (Glivec, Novartis Pharmaceutical, Basel, Switzerland), a small molecule tyrosine kinase inhibitor, is the first line of treatment for newly diagnosed chronic myeloid leukemia chronic phase patients. Earlier studies have suggested that continuous Bcr-Abl kinase inhibition by imatinib mesylate is a prerequisite for effective response. 1 Subsequent clinical pharmacokinetic and pharmacodynamic studies of imatinib mesylate showed significant responses with trough doses above 1 mM.
2 These set the paradigm for continuous Bcr-Abl kinase inhibition by imatinib mesylate, as the optimal strategy in chronic myeloid leukemia therapy. Recently Shah et al. 3 reported that transient potent Bcr-Abl kinase inhibition with 100 nM dasatinib is sufficient to commit Bcr-Abl þ cell lines to irreversible cell death. They also showed that transient intense and continuous partial Bcr-Abl kinase inhibition trigger equivalent cell death, showing the trade-off between duration and depth of kinase inhibition. This phenomenon was elicited in vitro with a concentration of imatinib (32.5 mM) far above that achievable pharmacologically, although the kinase inhibitory dose of dasatinib (100 nM) is clinically achievable. 3, 4 Despite reactivation of Bcr-Abl kinase within 8 h of dasatinib dosing, a randomized clinical trial comparing once versus twice a day dosing schedule of this drug showed equivalent responses in chronic myeloid leukemia chronic phase patients. 5 Nilotinib, a second generation tyrosine kinase inhibitor, is 30 times more potent than imatinib against Bcr-Abl kinase. However, nilotinib is less potent than dasatinib and has a more restricted spectrum of kinase inhibition. Moreover, nilotinib's in vivo half-life is 15 h, in contrast to that of dasatinib, which is 3-5 h. We, therefore, sought to assess the effect of short-term exposure to therapeutically achievable concentrations of nilotinib on Bcr-Abl kinase inhibition and cell death in chronic myeloid leukemia cell lines. 
Letters to the Editor
The Bcr-Abl þ cell lines, K562 (Figure 1 ) and KU812, were cultured with nilotinib (0-1 mM) for 30 min or 2 h, and reduction in Crkl phosphorylation (p-Crkl; surrogate marker of Bcr-Abl kinase activity) was assessed by Western blot. 6 Within 30 min of exposure, 1 mM nilotinib reduced p-Crkl by 85-90% of control. Next, K562 and KU812 cells were cultured with nilotinib (0-2 mM) either for short term (cells were cultured with nilotinib for 30 min, followed by thorough drug washout and reculture in drug-free medium for the remainder of 72 h) or for long term (cells were cultured with nilotinib for 30 min, followed by washout and reculture with nilotinib for a total of 72 h). Cell death was assessed by annexin V staining and trypan blue exclusion. Despite reactivation of Bcr-Abl kinase activity within 30 min of drug washout, short-term intense Bcr-Abl kinase inhibition with 1 mM nilotinib was able to trigger cell death equivalent to long-term partial kinase inhibition with 100 nM nilotinib (Figure 2a-c) . However, short-term 1 mM nilotinib did not trigger cell death in a Bcr-Abl negative cell line, HL-60 (Figure 2d) . Thus, our findings show that short-term intense Bcr-Abl kinase inhibition with nilotinib is sufficient to trigger cell death in Bcr-Abl þ cells. Shah et al. 3 suggested that cell death triggered by short-term culture with 100 nM dasatinib or 32.5 mM imatinib was related to specific Bcr-Abl kinase inhibition activity, rather than the combined effect of blockade of Bcr-Abl and Src family or other kinases. However, dasatinib and very high-dose imatinib inhibits a broad range of kinases, hence a critical role for off-target effects could not be ruled out. Our current study clarifies the central role of Bcr-Abl kinase inhibition. Nilotinib is more potent than imatinib against Bcr-Abl kinase, but unlike dasatinib, it has minimal activity against Src kinases (Manley PW et al. AACR annual meeting 2007, Vol. 48, abstract 3249). Dasatinib is approximately 10 times more potent than nilotinib and the cell death triggered by short-term 100 nM dasatinib and 1 mM nilotinib (equipotent concentration) are similar. Thus, our results and those of Shah et al. suggest that cell death triggered by short-term intense kinase inhibition with nilotinib or dasatinib is likely to be specifically due to Bcr-Abl kinase inhibition, rather than off-target effect.
With the current availability of two clinically approved and trialed second-generation Bcr-Abl inhibitors, it is important to gather evidence on their similarities and differences, to facilitate decisions regarding optimal dosing schedules. This data on nilotinib complement those on dasatinib and imatinib, 3 supporting the notion that short-term intense inhibition of the specifically targeted kinase is adequate to trigger irreversible cell death in oncogene-dependent cell lines. This is likely to be achievable clinically with dasatinib or nilotinib. This may change the paradigm of dosing and treatment schedule of tyrosine kinase inhibitors in general. 
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